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1 Glossary of Terms: Vision Screening 
Abnormal test result ƚĞƐƚƌĞƐƵůƚǁŚĞƌĞĂŶŽƌŵĂů “ƉĂƐƐ ?ƌĞƐƉŽŶƐĞĐŽƵůĚŶŽƚďĞ
detected under good conditions. The result on screening 
ĞƋƵŝƉŵĞŶƚŵĂǇŝŶĚŝĐĂƚĞ “ŶŽƌĞƐƉŽŶƐĞ ? ? “ĨĂŝů ? ?Žƌ “ƌĞĨĞƌ ? ?
Attendance rate The proportion of all those invited for screening that are tested 
and receive a result: 
 
x Invited for screening includes all those that are offered 
the screening test. 
x dĞƐƚĞĚĂŶĚƌĞĐĞŝǀĞĂƌĞƐƵůƚĐŽƵůĚďĞĂ “ƉĂƐƐ ?Žƌ “ƌĞĨƌƌĂů
ƚŽĚŝĂŐŶŽƐƚŝĐĂƐƐĞƐƐŵĞŶƚ ? ?
 
Attendance rate provides information on the willingness of 
families to participate in screening. 
Compliance with 
referral (percentage) 
The percentage of those who are referred from screening to a 
diagnostic assessment that actually attend the diagnostic 
assessment. 
 
Percentage of compliance provides information on the 
willingness of families to attend the diagnostic assessment after 
referral from screening. 
Coverage The proportion of those eligible for screening that are tested and 
receive a result: 
 
x Eligible for screening includes those within the population 
that are covered under the screening or health care 
programme. 
x Tested and receive a resulƚĐŽƵůĚďĞĂ “ƉĂƐƐ ?Žƌ “ƌĞĨĞƌƚŽ
ĚŝĂŐŶŽƐƚŝĐĂƐƐĞƐƐŵĞŶƚ ? ?
 
Factors such as being offered screening, willingness to 
participate, missed screening, ability to complete the screen, and 
ability to document the screening results will influence the 
coverage. 
False negatives The percentage of children with a visual deficit (defined by the 
ƚĂƌŐĞƚĐŽŶĚŝƚŝŽŶ ?ƚŚĂƚƌĞĐĞŝǀĞĂƌĞƐƵůƚŽĨ “ƉĂƐƐ ?ĚƵƌŝŶŐƐĐƌĞĞŶŝŶŐ ? 
 
Example: If 100 children with visual deficit are screened, and 1 
child passes the screening, the percentage of false negatives is 
1%. 
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False positives The percentage of children with normal vision that are referred 
from screening to a diagnostic assessment. 
Guidelines Recommendations or instructions provided by an authoritative 
body on the practice of screening in the country or region. 
Vision screening 
professional 
A person qualified to perform vision screening, according to the 
practice in the country or region. 
Inconclusive test 
result 
ƚĞƐƚƌĞƐƵůƚǁŚĞƌĞĂŶŽƌŵĂů “ƉĂƐƐ ?ƌĞƐƉŽŶƐĞĐŽƵůĚŶŽƚďĞ
detected due to poor test conditions or poor cooperation of the 
child.  
Invited for screening Infants/children and their families who are offered screening. 
Outcome of vision 
screening 
An indication of the effectiveness or performance of screening, 
such as a measurement of coverage rate, referral rate, number of 
children detected, etc. 
Untreated amblyopia Those children who have not received treatment for amblyopia 
due to missed screening or missed follow-up appointment. 
Persistent amblyopia Amblyopia that is missed by screening, or present after the child 
has received treatment. 
Positive predictive 
value 
The percentage of children referred from screening who have a 
confirmed vision loss. 
 
For example, if 100 babies are referred from screening for 
diagnostic assessment and 10 have normal vision and 90 have a 
confirmed visual defect, the positive predictive value would be 
90%. 
Prevalence The percentage or number of individuals with a specific disease 
or condition. Prevalence can either be expressed as a percentage 
or as a number out of 1000 individuals within the same 
demographic. 
Programme An organised system for screening, which could be based 
nationally, regionally or locally. 
Protocol Documented procedure or sequence for screening, which could 
include which tests are performed, when tests are performed, 
procedures for passing and referring, and so forth. 
Quality assurance A method for checking and ensuring that screening is functioning 
adequately and meeting set goals and benchmarks. 
Referral criteria A pre-determined cut-off boundary for when a child should be 
re-tested or seen for a diagnostic assessment.  
Risk babies / Babies 
at-risk 
All infants that are considered to be at-risk or have risk-factors 
for vision defects/ophthalmic pathology according to the 
screening programme. 
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Two common risk factors are admission to the neonatal-intensive 
care unit (NICU) or born prematurely. However, other risk factors 
for visual defects may also be indicated in the screening 
programme. 
Sensitivity The percentage of children with visual defects that are identified 
via the screening programme. 
 
For example, if 100 babies with visual defects are tested, and 98 
of these babies are referred for diagnostic assessment and 2 pass 
the screening, the sensitivity is 98%. 
Specificity The percentage of children with normal vision that pass the 
screening. 
 
For example, if 100 babies with normal vision are tested, and 10 
of these babies are referred for diagnostic assessment and 90 
pass the screening, the specificity is 90%. 
Target condition The visual defect you are aiming to detect via the screening 
programme. 
Well, healthy babies Infants who are not admitted into the NICU or born prematurely 
(born after a gestation period of less than 37 weeks).  
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2 Abbreviations 
ACT  Alternating Cover Test 
AR  Autorefraction 
AS  Automated Screening 
CT  Cover Test 
CV  Colour Vision 
EI Eye Inspection 
EM  Eye Motility 
Fix  Fixation 
GDP  Gross Domestic Product 
GP General Practitioner 
Hir  Hirschberg 
NICU Neonatal-intensive care unit 
PM Pursuit Movements 
PPP  Purchasing Power Parity 
PR  Pupillary Reflexes 
RE  Retinal Examination 
ROP Retinopathy of Prematurity 
RR  Red Reflex Testing 
SV  Stereopsis 
VA  Visual Acuity  
WHO  World Health Organisation 
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3 Population and Healthcare Overview 
The population of the Netherlands is 17,132,854 (World Bank, 2018a) and birth rate is 
estimated at 10.1 births/1,000 population in 2016 (World Bank, 2018b).The change in 
population and birth rate from 1960 to 2017 is shown in Figure 1, graphs A and B 
respectively. 
The Netherlands has a reported population density of 509 people per square kilometre in 
2017 and this has risen from 345 people per square kilometre in 1961 (World Bank, 2018c). 
In terms of healthcare facilities, the total density of hospitals in 2013 was 0.76 per 100,000 
population (WHO, 2016a). Infant mortality in 2017 is estimated at 3.3 deaths/1,000 live 
births in total (World Bank, 2018d). 
The average life expectancy in the Netherlands is estimated at 81.5 years (World Bank, 
2018e), with a death rate of 8.7 deaths/1,000 population in 2016 (World Bank, 2018f). The 
Netherlands has a gross national income per capita (PPP int. $, 2013) of $43,000 (WHO, 
2016b). The estimated total expenditure on health per capita in 2014 was $5,202 (Intl $) and 
the total expenditure on health in 2014 as percentage of GDP was 10.2% (WHO, 2016b). 
 
 
 
 
 
 
 
 
Summary Vision Screening Data: Netherlands                                                                                          
 
2 
 
Figure 1: Change in the Total Population and Birth Rate in the Netherlands between 1960 and 2017 
 
Source: Information sourced from World Bank (2018) 
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4 Vision Screening Commissioning and Guidance 
In the Netherlands, vision screening is organised nationally by 28 Youth Healthcare regions. 
All children in the Netherlands are offered the same package via the Basic Youth Healthcare 
(Basic JGZ) package. The Youth Doctors and Youth Nurses offer all care in the Netherlands to 
all children. However, flexibility in implementation is permitted, vision screeners are free to 
decide, together with the parent, whether certain elements are not carried out, or carried out 
in any other way. Local initiatives to omit vision screening are allowed. All regions do however 
provide vision screening and in general there are no differences. Vision screening is funded 
by the municipalities and it is embedded into a general preventative child healthcare 
screening system.  
The vision screening programme started regionally between 1965 and 1975, was 
implemented nationally between 1987 and 1989. The vision screening programme has been 
changed since its implementation; specifically, in 1987 the first non-binding guideline was 
published, the first national guideline was released in 2002 and a revision was implemented 
in 2010. This is currently under revision (2018). The NCJ (Netherlands Center for Youth (child) 
Healthcare) called for a revision of the guidelines after consulting the Ministry of Health, 
Welfare and Sport, they provide financial support by means of The Netherlands Organisation 
for Health Research and Development (ZonMw). There is no regular update. Although review 
has taken place, there have been no significant changes since 1987 when the addition of visual 
acuity measurement at 7 years was introduced.  
There are no methods for quality monitoring imposed by the government. However, it is 
carried out by the implementation process included in the development and continuing 
education, as a regulation for Youth Healthcare Doctors. There may be differences from 
region to region, but they will all follow and adhere to the guidelines as suggested by their 
associations. There has been research on the vision screening programme carried out in the 
Netherlands (Sloot et al., 2017; Sloot et al., 2015; Groenewoud et al. 2010). There has been 
no cost-effectiveness analysis in the Netherlands.  
Vision screening is conducted by Youth Nurses and Youth Doctors within approximately 1400 
centres. General professionals identified, that do not screen, but could do so with additional 
training include orthoptists, optometrists and general practitioners (GP). There is no specific 
training to perform vision screening. It is incorporated in the general medical training or Youth 
Doctor training (2 years) and the post-bachelor nursing degree (1 year part-time). The Youth 
Doctor degree has mandatory re-registration and the Nursing degree has voluntary re-
registration. In a period of 5 years, the Youth Doctor must have worked as a doctor for 2,080 
hours. Work experience only counts if it meets the requirements of the medical assessment 
framework. Additionally, the doctor needs to participate in a continuing education 
programme. Both Youth Doctor and Nursing degrees are accredited. 
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5 Screening programme  
The target conditions screened for in the Netherlands are retinopathy of prematurity (ROP) 
in premature infants, congenital cataract/ other congenital ocular abnormalities in all 
newborn infants and amblyopia in childhood. The health care professionals delivering vision 
screening, venue for screening and tests used vary depending on the age of the child as shown 
in Tables 1, 2 and 3 respectively. Specific details of the screening offered within each age 
group are described more fully in sections 5.1 to 5.4 below. 
5.1 Vision screening - Preterm babies 
ROP screening is performed on preterm babies born before 32 weeks and/or birth weight of 
less than 1500 grams. These babies also receive a fundus examination by an ophthalmologist. 
If these tests are positive, a further examination is conducted by an ophthalmologist as 
required. If the tests are negative (no ROP), tests conducted include eye inspection, fixation, 
red reflex testing, eye motility, Hirschberg test, retinal examination, pursuit movements 
(ŵŽŶŽĐƵůĂƌĂŶĚďŝŶŽĐƵůĂƌ ?, pupillary reflexes and cover test (near with fixation), all performed 
by either a nurse, specialist nurse, or Youth Doctor. These tests are conducted in a hospital 
and referral is determined by evidence of ROP, no or abnormal fixation at 1 month of age and 
no or abnormal fixation or pursuit at 2 months of age. 
5.2 Vision screening - Birth to 3 months 
Well, healthy babies up to the age of 3 months are screened by doctor in a child healthcare 
centre. Tests are conducted at 1-2 months of age and include eye inspection, fixation, red 
reflex testing, eye motility, Hirschberg test, pursuit movements  ?ŵŽŶŽĐƵůĂƌĂŶĚďŝŶŽĐƵůĂƌ ?, 
pupillary reflexes and near fixation cover test. Referral is needed after two abnormal or two 
inconclusive test results. Criteria that determine referral are absence of red reflex, no or 
abnormal fixation at 1 month of age and no or abnormal pursuit at 2 months of age. 
5.3 Vision screening - 3 months to 36 months 
Children aged between 3 to 36 months are screened by a specialist nurse or a Youth Doctor 
in a child ŚĞĂůƚŚĐĂƌĞĐĞŶƚƌĞ ?^ĐƌĞĞŶŝŶŐŝƐĐŽŶĚƵĐƚĞĚĂƚ ?
x  ? ? ?ŵŽŶƚŚƐ ?ĞǇĞŝŶƐƉĞĐƚŝŽŶ ?ƉƵƉŝůůĂƌǇƌĞĨůĞǆĞƐĂŶĚƌĞĚƌĞĨůĞǆƚĞƐƚŝŶŐ 
x  ? ? ? ŵŽŶƚŚƐ ? ĞǇĞ ŝŶƐƉĞĐƚŝŽŶ ? ƉƵƉŝůůĂƌǇ ƌĞĨůĞǆĞƐ ? ƌƵĐŬŶĞƌ ĂŶĚ ŶĞĂƌ ĐŽǀĞƌ ƚĞƐƚ  ? ĞǇĞ
ŵŽƚŝůŝƚǇĂŶĚƉƵƌƐƵŝƚŵŽǀĞŵĞŶƚƐ ?ŵŽŶŽĐƵůĂƌĂŶĚďŝŶŽĐƵůĂƌ ? 
x  ? ? ? ? ?ŵŽŶƚŚƐ ?ĞǇĞ ŝŶƐƉĞĐƚŝŽŶ ?ƉƵƉŝůůĂƌǇ ƌĞĨůĞǆĞƐ ?ƌƵĐŬŶĞƌĂŶĚŶĞĂƌĐŽǀĞƌ ƚĞƐƚ ?ĞǇĞ
ŵŽƚŝůŝƚǇĂŶĚƉƵƌƐƵŝƚŵŽǀĞŵĞŶƚƐ ?ŵŽŶŽĐƵůĂƌĂŶĚďŝŶŽĐƵůĂƌ ? 
&ƵƌƚŚĞƌĐƌŝƚĞƌŝĂƚŚĂƚĚĞƚĞƌŵŝŶĞƌĞĨĞƌƌĂůĨŽƌĨƵƌƚŚĞƌĚŝĂŐŶŽƐƚŝĐĞǆĂŵŝŶĂƚŝŽŶĂƌĞĨĂŝůƵƌĞƚŽĨŝǆŝŶŐ
ĨŝǆŽŶŽǁŶŚĂŶĚƐĂƚ ?ŵŽŶƚŚƐ ?ZĞĨĞƌƌĂůŝƐŶĞĞĚĞĚĂĨƚĞƌƚǁŽĂďŶŽƌŵĂůŽƌƚǁŽŝŶĐŽŶĐůƵƐŝǀĞƚĞƐƚ
ƌĞƐƵůƚƐ ? ? 
Summary Vision Screening Data: Netherlands                                                                                 
 
5 
 
5.4 Vision screening - 36 months to 7 years 
Children aged between 36 months up to 7 years of age are screened by a specialist nurse, 
Youth Doctor, or a practice assistant in a child healthcare centre. The test conducted at this 
age include: 
x  ? ?zĞĂƌƐŽĨĂŐĞ ?Visual acuity (VA) (Specialist nurse; nurse practitioner; child healthcare 
doctor). &ƵƌƚŚĞƌĂƐƐĞƐƐŵĞŶƚƐĐĂŶďĞĐŽŶĚƵĐƚĞĚŽŶŝŶĚŝĐĂƚŝŽŶŽĨĂďŶŽƌŵĂůŝƚǇ ?dŚĞƐĞ
ŝŶĐůƵĚĞĞǇĞŝŶƐƉĞĐƚŝŽŶ ?ƉƵƉŝůůĂƌǇƌĞĨůĞǆĞƐ ?ƌƵĐŬŶĞƌĂŶĚŶĞĂƌĐŽǀĞƌƚĞƐƚ ?ĞǇĞŵŽƚŝůŝƚǇ
ĂŶĚďŝŶŽĐƵůĂƌƉƵƌƐƵŝƚŵŽǀĞŵĞŶƚƐ ?ŚŝůĚŚĞĂůƚŚĐĂƌĞĚŽĐƚŽƌ ?ŶƵƌƐĞƉƌĂĐƚŝƚŝŽŶĞƌ ?
x  ? ? ? ?zĞĂƌƐ ŽĨ ĂŐĞ ?VA (Specialist nurse; nurse practitioner; child healthcare doctor). 
&ƵƌƚŚĞƌĂƐƐĞƐƐŵĞŶƚƐĐĂŶďĞĐŽŶĚƵĐƚĞĚŽŶŝŶĚŝĐĂƚŝŽŶŽĨĂďŶŽƌŵĂůŝƚǇ ?dŚĞƐĞŝŶĐůƵĚĞĞǇĞ
ŝŶƐƉĞĐƚŝŽŶ ?ƉƵƉŝůůĂƌǇƌĞĨůĞǆĞƐ ?ƌƵĐŬŶĞƌĂŶĚŶĞĂƌĐŽǀĞƌƚĞƐƚ ?ĞǇĞŵŽƚŝůŝƚǇĂŶĚďŝŶŽĐƵůĂƌ
ƉƵƌƐƵŝƚŵŽǀĞŵĞŶƚƐ ?ŚŝůĚŚĞĂůƚŚĐĂƌĞĚŽĐƚŽƌ ?ŶƵƌƐĞƉƌĂĐƚŝƚŝŽŶĞƌ ? 
x  ?ƚŽ  ? ?zĞĂƌƐŽĨĂŐĞ ?VA (practice assistant; specialist nurse; nurse practitioner; child 
healthcare doctor). &ƵƌƚŚĞƌ ĂƐƐĞƐƐŵĞŶƚƐ ĐĂŶ ďĞ ĐŽŶĚƵĐƚĞĚ ŽŶ ŝŶĚŝĐĂƚŝŽŶ ŽĨ
ĂďŶŽƌŵĂůŝƚǇ ?dŚĞƐĞŝŶĐůƵĚĞĞǇĞŝŶƐƉĞĐƚŝŽŶ ?ƉƵƉŝůůĂƌǇƌĞĨůĞǆĞƐ ?ƌƵĐŬŶĞƌĂŶĚŶĞĂƌĐŽǀĞƌ
ƚĞƐƚ ?ĞǇĞ ŵŽƚŝůŝƚǇĂŶĚďŝŶŽĐƵůĂƌƉƵƌƐƵŝƚŵŽǀĞŵĞŶƚƐ  ?ŚŝůĚŚĞĂůƚŚĐĂƌĞĚŽĐƚŽƌ ?ŶƵƌƐĞ
ƉƌĂĐƚŝƚŝŽŶĞƌ ? 
VA is measured using the Amsterdam picture chart at ages 3 to 3.9 years of age. The optotypes 
charts are based on the Snellen principle and are used at 5-metre test distance with optotype 
sizes of 30, 20, 15, 10, 6 and 5.  
Children aged 5 and 7 years have visual acuity measured with the Landolt C which are linear 
logMAR charts (at 5 metres) with optotype sizes of 0.1, 0.12, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.65, 
0.8, and 1.0. Referral is needed after two abnormal, or two inconclusive test results. Criteria 
that determine referral for further diagnostic examination are detailed as:  
Ɣ 3 years of age  ? VA of less than 5/6 Snellen (0.8 decimal, 0.1 logMAR) in one or both 
eyes 
Ɣ 3.9 years of age  ? VA with Landolt C of worse than 0.5 decimal (0.3 logMAR, 6/12 
Snellen equivalent) in both eyes  
Ɣ 5 years of age  ? VA with Landolt C of worse than 0.8 decimal (0.1 logMAR, 6/7.5 
Snellen equivalent) in both eyes (not allowing >0.1 line of intraocular difference) 
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Table 1: Healthcare professionals who conduct vision screening in each age group  
Table 1 Youth doctor Ophthalmologist Nurse Specialist nurse Doctor Practice assistant 
Preterm babies  
 
9 
 
9 
 
9 
 
9 × × 
0 to 3 months  
× × × × 
 
9 × 
3 to 36 months  
 
9 × 
 
9 
 
9 
 
9 × 
3 to 7 years  
 
9 × × 
 
9 × 
 
9 
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Table 2: Vision screening tests used in vision screening for each age group  
Table 2 
ROP Eye 
inspection 
Fixation  Red 
reflex  
Eye 
motility 
Hirschberg Retinal 
examination 
Pursuit 
movements 
Pupillary 
reflexes 
Cover 
test 
Visual 
acuity  
Preterm 
babies  
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 
 
9 × 
0 to 3 
months  × 
 
9 
 
9 
 
9 
 
9 
 
9 × 
 
9 
 
9 
 
9 
× 
 
 
3 to 36 
months  × 
 
9 × 
 
9 
 
9 × × 
 
9 
 
9 
 
9 
× 
 
 
3 to 7 
years  × 
 
9 × × 
 
9 × × 
 
9 
 
9 
 
9 
 
9 
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Table 3: Location of vision screening for each age group  
Table 3 Hospital Child healthcare centre 
Preterm babies  9 × 
0 to 3 months  × 9 
3 to 36 months  × 9 
3 to 7 years  × 9 
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6 Automated Screening 
Automated vision screening is achieved using handheld, portable devices designed to detect 
presence of refractive error from 6 months of age. It provides objective results and is used to 
detect amblyopic risk factors. This differs from other methods used to screen children for 
amblyopia which focus on detection of the actual condition and the resulting visual loss. No 
automated screening is conducted in the Netherlands.  
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7 Provision for Visually Impaired  
The Netherlands has 10 schools for blind or severely visually impaired children. It was 
estimated that in 2012, 750 children (aged 3-20 years) attended these schools. The costs per 
child include funding of 15,700 Euros plus basic funding of 6,100 Euros, totalling 21,800 Euros 
per child; basic funding is the amount paid for every child for education and the rest of the 
funding is added due to the special needs. There is support for visually impaired children that 
attend regular mainstream primary school, including digital instruments and there is also 
additional funding of up to 15,200 Euros per child for visual impairment needs, covered by 
the Ministry of Education.  
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8 Knowledge of existing screening programme 
8.1 Prevalence/Diagnosis  
A 7-year birth cohort study of 4,624 children was started in 1996/1997 in Rotterdam 
(Groenewoud, 2010), this investigated the detection and causes of amblyopia. The findings 
were as follows:  
Ɣ The prevalence of treated or untreated amblyopia between birth and 6 years was 3.4%  
Ɣ The prevalence of persistent amblyopia at >7 years of age was 0.78% 
Ɣ The prevalence of strabismus at age 6 was 1.6% and at age 7 was 1.8% 
Ɣ Of 102 children diagnosed with amblyopia, the incidence of the four types were 42 
refractive, 32 combined mechanism, 19 strabismus, 7 deprivation, 2 unknown. 
 
A paper written in 2018, which is currently only available at abstract (Klaver et al., 2015), 
investigated the prevalence of ocular conditions found in 6,690 children in Rotterdam at age 
of 6 years and found:  
Ɣ Eye injury (Foreign body) 0.3% 
Ɣ Nasolacrimal duct obstruction 0.8% 
Ɣ Congenital ocular toxoplasmosis 0.2% 
Ɣ Orbital cellulitis 0.1% 
Ɣ Congenital ptosis 0.7% 
Ɣ Psychogenic amblyopia 0.1% 
Ɣ Retinopathy of prematurity (ROP) 0.2% 
Ɣ Retinoblastoma 0.1% 
Ɣ Congenital cataract 0.4% 
Ɣ Dominant optic atrophy 0.1% 
Ɣ Conjunctivitis 0.6% 
Ɣ Coloboma of iris and choroid (including macula) 0.1% 
Ɣ Hordeolum 0.2% 
Ɣ Optic nerve head drusen 0.1% 
Ɣ Shaken baby retinopathy 0.1% 
Ɣ Myopic degeneration 0.2% 
Ɣ Subnormal visual acuity 0.8% 
Ɣ Chalazion 0.3% 
Ɣ Eye strain 0.1% 
Ɣ Transient subnormal visual acuity 0.2% 
Ɣ Migraine 0.1% 
Ɣ Susceptible for developing a retinopathy 0.2% 
Ɣ Marfan syndrome with lens luxation 0.1% 
Ɣ Capillary hemangioma 0.1% 
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Ɣ Optic nerve disorders 0.1% 
Ɣ Infantile nystagmus syndrome 0.2% 
Ɣ Congenital blepharophimosis syndrome (BPES) 0.1% 
Ɣ Congenital fibrosis of the extraocular muscles (CFEOM) 0.1% 
Ɣ Uveitis 0.1% 
8.2 Coverage 
All children are invited for vision screening and attendance to visual screening is estimated 
at:  
Ɣ 1st screening- 100% 
Ɣ 2nd screening - 99.5% 
Ɣ 3rd screening - 94% 
Ɣ 4th screening - 89.1% 
Ɣ 5th screening - 84.1%  
 
Attendance to VA measurement is estimated at: 
Ɣ 1st screening - 90% 
Ɣ 2nd screening - 89.1% 
Ɣ 3rd screening - 84.1% 
 
8.3 Screening evaluation 
There is no national registration or documentation of noncompliance with referral after an 
abnormal screening test result. Groenewoud et al. (2010) found that:  
Ɣ The percentage of compliance with referral after an abnormal screening test result 
was 73.62%, with 26.38% not attending referral for diagnostic assessment.  
Ɣ The percentage of false negatives was 0.91% 
Ɣ The percentage of false positive was 0.91% 
Ɣ The positive predictive value was 91% 
 
The diagnosis of amblyopia was made when the children were age 7-years, at the final 
examination of the study, 2964 children attended that extra screen, 27 of which had a false 
negative screen result but were diagnosed with amblyopia in this extra screen. 
de Koning et al. (2013) investigated the effectiveness of screening for amblyopia and other 
eye disorders in a prospective 7-year birth cohort study (n=4,624) using the same dataset as 
the previously mentioned Groenewoud (2010) study. They report:  
Ɣ The sensitivity of the Dutch vision screening programme was 73% at age 7 years 
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Ɣ The specificity of the Dutch vision screening programme was 83% at age 7 years 
 
It is estimated, based on the data from Groenewoud (2010) that within the 200,000 newborn 
in Netherlands per year, there was approximately 6,000 (3%) new amblyopia cases, 4,000 
(2%) new strabismus cases and 120 (0.06%) new congenital cataract cases.  
8.4 Treatment success 
The number of children treated for strabismus and amblyopia was also determined by 
Groenewoud et al. (2010) as follows:  
Ɣ The percentage of children treated for strabismus, after being screened before the 
age of 7 years is 0.0145% 
Ɣ The percentage of all children treated for strabismus is 1.69% 
Ɣ The percentage of children treated for amblyopia, after being screened before the age 
of 7 years is 2.46% 
Ɣ The percentage of all children treated for amblyopia is 3.37%  
Ɣ The distribution of strabismic, refractive, combined-mechanism and deprivation 
amblyopia are: 
o strabismic amblyopia 22% 
o refractive amblyopia 34% 
o combined-mechanism amblyopia 34% 
o deprivation amblyopia 7% 
o unknown 3% 
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9 Costs of vision screening in children 
9.1 Cost of vision screening  
The maximum salary costs per year for vision screening professionals is 44,000 Euros and 93 
Euros per hour. The cost to train a nurse is estimated at between 10,000 and 18,000 Euros 
and for a doctor this rises to between 40,000 and 60,000 Euros. The total screening costs per 
year and per child per year for vision screening is not known. The total annual cost of all 
screening:  
Ɣ 433 million Euros annual costs (323 million from municipalities and 110 million from 
vaccination programmes) 
Ɣ Total screening cost for all screening (not just vision) is 108 Euros, per year, per child  
9.2 Cost of treatment for amblyopia 
All treatments are covered by health insurance; the local municipality, who receive a 
municipality fund from the national government, pays child healthcare centres. However, 
glasses will cost the parents between 100 and 600 Euros per pair, unless the prescription rises 
ĂďŽǀĞ ?ĚŝŽƉƚƌĞƐƉŚĞƌĞƐĂŶĚƚŚĞĂĐƚƵĂůĐŽƐƚƚŽƉĂƌĞŶƚƐǁŝůůĚĞƉĞŶĚŽŶƚŚĞŝŶĚŝǀŝĚƵĂů ?ƐŚĞĂůƚŚ
insurance. Special regulations are in place concerning any hyperopic correction in case of 
accommodative esotropia. Specifically, the treating orthoptists states in a letter to the 
insurance company that this child has accommodative esotropia or congenital cataracts, after 
that, the insurance company pays for the glasses/contact lenses. 
9.3 Cost of Treatment for strabismus  
 The estimated costs for strabismus surgery, including follow-up:  
Ɣ Average total of 2,045 Euros 
Ɣ Ophthalmologist (1 year) costs: 700 Euros 
Ɣ Orthoptist (2 years) costs (10 visits): 800 Euros 
9.4 Cost of treatment for cataract 
The estimated costs for congenital cataract surgery, including follow up of deprivation 
amblyopia:  
Ɣ Surgery and visits round surgery: 635-2,146 Euros.  
Ɣ Glasses (6 pairs during 10 years) 6 pairs at 500 Euros each: Total cost = 3,000 Euros 
Ɣ Visits 2x per year ophthalmologist at 700 Euros over 10 years: Total cost = 7,000 Euros 
Ɣ Visits 6x per year over first 5 years orthoptist: 30 visits at 80 Euros: Total cost = 2,400 
Euros 
Ɣ Visits 2x per year over second 5 years orthoptist: 10 visits at 80 Euros: Total cost = 800 
Euros 
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